FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,704 | -97.1% | 19,200 | -86.2% | 0.00% | -100.0% |
| Q4 2022 | $1,402,510 | -26.2% | 139,000 | +63.8% | 0.01% | -25.0% |
| Q3 2022 | $1,901,000 | -23.7% | 84,856 | -15.6% | 0.02% | -33.3% |
| Q2 2022 | $2,493,000 | +564.8% | 100,592 | +2343.3% | 0.02% | +380.0% |
| Q4 2020 | $375,000 | +3.0% | 4,117 | -54.8% | 0.01% | -28.6% |
| Q3 2020 | $364,000 | -75.7% | 9,113 | -90.5% | 0.01% | -84.1% |
| Q3 2019 | $1,496,000 | +547.6% | 96,400 | +748.2% | 0.04% | +450.0% |
| Q2 2019 | $231,000 | -87.8% | 11,365 | -90.2% | 0.01% | -90.5% |
| Q3 2018 | $1,891,000 | – | 116,100 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |